| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11191753 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(10 years from now) | |
| US10624879 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(10 years from now) | |
| US9827231 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(10 years from now) | |
Clenpiq is owned by Ferring Pharms Inc.
Clenpiq contains Citric Acid; Magnesium Oxide; Sodium Picosulfate.
Clenpiq has a total of 3 drug patents out of which 0 drug patents have expired.
Clenpiq was authorised for market use on 28 November, 2017.
Clenpiq is available in solution;oral dosage forms.
Clenpiq can be used as for cleansing of the colon as a preparation for colonoscopy, for cleansing the large intestine as a preparation for colonoscopy.
The generics of Clenpiq are possible to be released after 26 June, 2034.
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy
Dosage: SOLUTION;ORAL
CLENPIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic